$SNDX
Syndax Pharmaceuticals Inc

2022 Q3 Form 10-Q Financial Statement

#000095017022015523 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.240M $7.990M $6.836M
YoY Change 21.16% 36.77% 20.56%
% of Gross Profit
Research & Development $26.90M $29.73M $30.02M
YoY Change 5.06% 76.24% 37.27%
% of Gross Profit
Depreciation & Amortization $8.000K $11.00K $11.00K
YoY Change 0.0% 120.0% -45.0%
% of Gross Profit
Operating Expenses $35.14M $37.72M $30.02M
YoY Change 8.44% 66.09% 9.0%
Operating Profit -$35.14M -$37.72M -$36.86M
YoY Change 75.42% 68.91% 35.69%
Interest Expense $1.748M $695.0K $651.0K
YoY Change -408.83% 9.62% 4.49%
% of Operating Profit
Other Income/Expense, Net -$262.0K $152.0K $116.0K
YoY Change 539.02% -126.39% -293.33%
Pretax Income -$35.40M -$37.57M -$37.17M
YoY Change 71.53% 64.0% 34.09%
Income Tax
% Of Pretax Income
Net Earnings -$35.40M -$37.57M -$37.17M
YoY Change 71.53% 64.0% 34.07%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58 -$0.62 -$0.63
Diluted Earnings Per Share -$0.58 -$0.62 -$630.2K
COMMON SHARES
Basic Shares Outstanding 56.57M 60.16M 58.98M
Diluted Shares Outstanding 60.67M 60.16M 58.98M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $350.7M $376.7M $410.9M
YoY Change 48.47% 44.85% 48.77%
Cash & Equivalents $71.38M $120.2M $188.8M
Short-Term Investments $279.3M $256.4M $222.1M
Other Short-Term Assets $1.974M $2.097M $8.989M
YoY Change 6.3% 1.16% 259.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $357.6M $392.3M $420.1M
YoY Change 50.11% 49.41% 50.61%
LONG-TERM ASSETS
Property, Plant & Equipment $23.00K $256.0K $1.139M
YoY Change -98.16% -49.21% 89.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $12.13M
YoY Change
Other Assets $881.0K $995.0K $1.027M
YoY Change 927.0%
Total Long-Term Assets $2.056M $14.15M $2.166M
YoY Change 64.35% 2707.54% 170.75%
TOTAL ASSETS
Total Short-Term Assets $357.6M $392.3M $420.1M
Total Long-Term Assets $2.056M $14.15M $2.166M
Total Assets $359.7M $406.4M $422.2M
YoY Change 50.18% 54.5% 50.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.115M $6.438M $8.231M
YoY Change 38.91% 77.65% 26.63%
Accrued Expenses $13.68M $17.27M $18.75M
YoY Change -2.96% 42.5% 57.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000K $7.214M $3.568M
YoY Change -99.96% 2.62% -22.43%
Total Short-Term Liabilities $20.80M $30.93M $30.55M
YoY Change -27.55% 27.31% 24.19%
LONG-TERM LIABILITIES
Long-Term Debt $14.00K $13.00M $16.48M
YoY Change -99.87% -2.41% 5.63%
Other Long-Term Liabilities $768.0K $570.0K $643.0K
YoY Change -3.76% -94.76% -94.31%
Total Long-Term Liabilities $782.0K $13.57M $17.12M
YoY Change -93.37% -43.93% -36.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.80M $30.93M $30.55M
Total Long-Term Liabilities $782.0K $13.57M $17.12M
Total Liabilities $21.59M $44.50M $47.67M
YoY Change -46.7% -8.25% -7.43%
SHAREHOLDERS EQUITY
Retained Earnings -$653.8M -$618.4M
YoY Change -0.13%
Common Stock $993.6M $981.7M
YoY Change 17.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $338.1M $361.9M $374.5M
YoY Change
Total Liabilities & Shareholders Equity $359.7M $406.4M $422.2M
YoY Change 50.18% 54.5% 50.96%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$35.40M -$37.57M -$37.17M
YoY Change 71.53% 64.0% 34.07%
Depreciation, Depletion And Amortization $8.000K $11.00K $11.00K
YoY Change 0.0% 120.0% -45.0%
Cash From Operating Activities -$28.54M -$40.31M -$41.93M
YoY Change 14.43% 67.63% 85.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$6.793M -$49.95M $8.182M
YoY Change -125.51% -330.37% -127.99%
Cash From Investing Activities -$6.793M -$49.95M $8.182M
YoY Change -125.51% -330.37% -127.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.53M 21.72M 557.0K
YoY Change -893.26% 260.8% -41.98%
NET CHANGE
Cash From Operating Activities -28.54M -40.31M -41.93M
Cash From Investing Activities -6.793M -49.95M 8.182M
Cash From Financing Activities -13.53M 21.72M 557.0K
Net Change In Cash -48.86M -68.53M -33.19M
YoY Change -1540.51% -1973.54% -34.73%
FREE CASH FLOW
Cash From Operating Activities -$28.54M -$40.31M -$41.93M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56565165
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120239000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001395937
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37708
dei Entity Registrant Name
EntityRegistrantName
Syndax Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
419-1400
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SNDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Assets
Assets
449657000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6438000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5669000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
152000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3938
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221965000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
115000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
115000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
246552000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
217971000
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
9887000
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6894000
CY2022Q2 sndx Collaboration Receivable
CollaborationReceivable
13102000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2392000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1451000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
392287000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
448396000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
12125000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
278000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
774000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
983000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
995000
CY2022Q2 us-gaap Assets
Assets
406437000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16974000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14465000
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
7212000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
299000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
361000
CY2022Q2 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
2000
CY2021Q4 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
1000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
187000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30925000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20683000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
570000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
711000
CY2022Q2 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
8000
CY2022Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
12994000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19895000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13572000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
20606000
CY2022Q2 us-gaap Liabilities
Liabilities
44497000
CY2021Q4 us-gaap Liabilities
Liabilities
41289000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-50000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56399734
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56399734
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54983105
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54983105
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
981712000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
952019000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1335000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
45000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-618443000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-543702000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
361940000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
406437000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
449657000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
379000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
758000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
379000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
758000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29734000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16871000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59756000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38742000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7990000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5842000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14827000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11513000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
37724000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
22713000
us-gaap Operating Expenses
OperatingExpenses
74583000
us-gaap Operating Expenses
OperatingExpenses
50255000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37724000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22334000
us-gaap Operating Income Loss
OperatingIncomeLoss
-74583000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49497000
CY2022Q2 us-gaap Interest Expense
InterestExpense
695000
CY2021Q2 us-gaap Interest Expense
InterestExpense
634000
us-gaap Interest Expense
InterestExpense
1346000
us-gaap Interest Expense
InterestExpense
1258000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
878000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
108000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1103000
us-gaap Investment Income Interest
InvestmentIncomeInterest
229000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60156653
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60156653
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-576000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-158000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1136000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22910000
us-gaap Net Income Loss
NetIncomeLoss
-74741000
us-gaap Net Income Loss
NetIncomeLoss
-50633000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1380000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
21000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38267000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22902000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76121000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50612000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37572000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22910000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74741000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50633000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51603286
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51603286
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59570888
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59570888
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51551844
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51551844
us-gaap Profit Loss
ProfitLoss
-74741000
us-gaap Profit Loss
ProfitLoss
-50633000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
22000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
25000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
320000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-300000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
209000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
197000
us-gaap Paid In Kind Interest
PaidInKindInterest
311000
us-gaap Paid In Kind Interest
PaidInKindInterest
234000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
187000
us-gaap Share Based Compensation
ShareBasedCompensation
7416000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47202000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222080000
us-gaap Share Based Compensation
ShareBasedCompensation
6007000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4930000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2357000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
13102000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
769000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
116000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-758000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2316000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
235000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82237000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46634000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
164632000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
126548000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
122866000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
119000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41766000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7548000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19427000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5131000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
150000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
143000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2700000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1706000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22277000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6980000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-101726000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115358000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120354000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68156000
us-gaap Interest Paid Net
InterestPaidNet
960000
us-gaap Interest Paid Net
InterestPaidNet
996000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc. (“we,” “us,” “our” or the “Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> in 2005. We base our operations in Waltham, Massachusetts and we operate in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> segment.</span></p>
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
183000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
150000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60156653
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</span></p>
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60156653
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51603286
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51603286
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59570888
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59570888
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51551844
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51551844
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22910000
us-gaap Net Income Loss
NetIncomeLoss
-74741000
us-gaap Net Income Loss
NetIncomeLoss
-50633000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37572000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-37572000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22910000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22910000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74741000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-74741000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50633000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-50633000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.00
CY2021Q1 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
250000
CY2021Q4 sndx Number Of Pre Funded Warrants Cashless Exchanged For Common Stock
NumberOfPreFundedWarrantsCashlessExchangedForCommonStock
475784
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37169000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
374549000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7416000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6007000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
187000
sndx Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
-187000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
312003000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1335000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
310669000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
343074000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
70000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
343119000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1564000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
642000
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
410000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
429000
CY2022Q2 sndx Prepaid Subscriptions
PrepaidSubscriptions
235000
CY2021Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
230000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16974000
CY2022Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
19427
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14465000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4342000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
553000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
662000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3166000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2022Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
58
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1701000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2392000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1451000
CY2022Q2 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
10519000
CY2021Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
7760000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2736000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3938000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3240000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3938000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3240000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7416000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6007000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7778
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
286572
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2700000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
191394
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1700000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
14765000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5235000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2022Q2 sndx Amortized Losses Reacquired Debt Noncurrent
AmortizedLossesReacquiredDebtNoncurrent
293000
CY2022Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
87000
CY2022Q2 us-gaap Loans Payable
LoansPayable
20206000
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
7212000
CY2022Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
12994000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3478000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-685000
CY2022Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
92000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2235
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
361940000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
252188000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2767000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
79000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
881000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-27723000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228205000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3240000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2021Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
64000
CY2021Q2 sndx Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
200000
CY2021Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
5131000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
825000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22910000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
214563000

Files In Submission

Name View Source Status
0000950170-22-015523-index-headers.html Edgar Link pending
0000950170-22-015523-index.html Edgar Link pending
0000950170-22-015523.txt Edgar Link pending
0000950170-22-015523-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-20220630.htm Edgar Link pending
sndx-20220630.xsd Edgar Link pending
sndx-ex10_1.htm Edgar Link pending
sndx-ex31_1.htm Edgar Link pending
sndx-ex31_2.htm Edgar Link pending
sndx-ex32_1.htm Edgar Link pending
sndx-20220630_def.xml Edgar Link unprocessable
sndx-20220630_lab.xml Edgar Link unprocessable
sndx-20220630_pre.xml Edgar Link unprocessable
sndx-20220630_htm.xml Edgar Link completed
sndx-20220630_cal.xml Edgar Link unprocessable